One NICE pathway and one NHS clinical-policy route: oral migalastat (HST4) for amenable mutations, ERT commissioned outside the TA process for the rest, with pegunigalsidase now NICE-recommended (TA915) as a third option for suboptimal responders.
NHS Highly Specialised Services commission Fabry Disease management at lysosomal storage disorder centres (GSTT/King's, Manchester, Addenbrooke's, Birmingham, Edinburgh, Belfast), covering an estimated 800 diagnosed UK patients. Agalsidase beta (Fabrazyme) remains the dominant ERT with roughly 600 patients on therapy; it has never gone through a formal NICE technology appraisal and is instead commissioned directly by NHS England under clinical policy. Migalastat (Galafold, NICE HST4, 2017) offers an oral alternative for the subset with an amenable GLA mutation, confirmed via HEK cell assay at NHS genetics laboratories, with roughly 200 UK patients on oral therapy, an estimated 25% of diagnosed patients.
NICE HST4 (2017) is one of the earliest complete positive HTA decisions for migalastat globally, roughly eight years ahead of most lower-income markets, reflecting a mature and well-structured UK access pathway. The most recent commercial event is pegunigalsidase alfa (Elfabrio, Chiesi/Protalix), a PEGylated ERT positioned for the 80-120 UK patients showing suboptimal response to agalsidase beta: anti-drug antibody positivity, inadequate GL-3 clearance, or continued organ progression. Its NICE appraisal has now concluded as TA915, recommended with an agreed commercial arrangement (PAS discount) already in place.
NHS-commissioned Fabry Disease agents — UK, 2026
| Drug (Brand / INN) | Mechanism | Company | UK Regulatory / NICE Status | Key Trial Result | NHS Commissioning |
|---|---|---|---|---|---|
| Fabrazyme (agalsidase beta) | ERT IV | Sanofi Genzyme | MHRA approved; no formal NICE technology appraisal — NHS-commissioned via clinical policy | Used for symptomatic renal/cardiac/neurological involvement (Phase 3 RCT); no NICE cost-effectiveness review has been conducted | NHS HSS commissioned; ~600 UK patients; dominant ERT |
| Galafold (migalastat) | Oral chaperone — mutation-specific | Amicus | MHRA approved; NICE HST4 (2017) recommended with PAS | Recommended for adults with amenable GLA mutation (ATTRACT/FACETS) | NHS commissioned with PAS; ~200 UK patients; HEK assay via NHS genetics labs |
| Elfabrio (pegunigalsidase alfa) | PEGylated ERT IV | Chiesi/Protalix | MHRA approved 2023; NICE TA915 recommended with commercial arrangement | Non-inferior to agalsidase beta on eGFR (BALANCE) | NHS commissioned with PAS following TA915; available for suboptimal ERT responders |
Sources: MHRA product licences; NHS England clinical commissioning policy for enzyme replacement therapy in Fabry disease (agalsidase beta — no dedicated NICE technology appraisal); NICE HST4 Migalastat for treating Fabry disease (2017); NICE TA915 Pegunigalsidase alfa for treating Fabry disease; UK Fabry Outcome Survey (FOS) 2023.
What this brief answers
Every section answers a named commercial question your team is asking, scoped to your asset.
Delivers
- NICE HST4 amenable-mutation eligibility criteria
- HEK assay access at NHS genetics laboratories
- the oral-versus-ERT routing logic in practice
Delivers
- BALANCE trial non-inferiority data versus agalsidase beta
- the suboptimal-responder definition NICE applied
- the PAS discount structure behind the TA915 recommendation
Delivers
- Prescribing posture at GSTT/King's, Manchester, Addenbrooke's, Birmingham, Edinburgh and Belfast
- anti-drug antibody and organ-progression switch criteria
Custom brief delivered in 72 hours.
Commission This BriefWhat's inside
- Why NHS Highly Specialised Services commission Fabry disease management at six named lysosomal storage disorder centres for roughly 800 diagnosed UK patients
- How agalsidase beta's NHS commissioning via clinical policy, without a formal NICE technology appraisal, differs from migalastat's and pegunigalsidase's HTA-reviewed status
- Full profiles of agalsidase beta (Fabrazyme), migalastat (Galafold, NICE HST4) and pegunigalsidase alfa (Elfabrio, NICE TA915)
- Mechanism, sponsor, trial evidence and NHS commissioning status for all three agents, from Sanofi Genzyme through Amicus and Chiesi/Protalix
- Why agalsidase beta reaches NHS patients through clinical commissioning policy while migalastat required a formal NICE HST4 recommendation
- How NICE's 2017 HST4 decision for migalastat placed the UK roughly eight years ahead of most lower-income markets on HTA maturity
- Why pegunigalsidase alfa is positioned for the 80-120 UK patients showing suboptimal response to agalsidase beta, via antibody positivity or inadequate GL-3 clearance
- How its NICE TA915 recommendation, with an agreed commercial arrangement already in place, resolves the suboptimal-responder segment's access question
- Why a HEK cell assay confirming an amenable GLA mutation, run at NHS genetics laboratories, gates access to oral migalastat therapy
- How roughly 200 of the estimated 800 diagnosed UK patients, about 25%, are routed to oral therapy rather than IV ERT
- How prescribing concentrates at GSTT/King's, Manchester, Addenbrooke's, Birmingham, Edinburgh and Belfast, the six NHS lysosomal storage disorder centres
- Why anti-drug antibody positivity and organ-progression evidence, not physician preference, trigger switches between the three agents
Included with every brief
How AXLRx builds this brief
Prepared by MoatRx analysts.
Every AXLRx brief is built from primary regulatory sources (MHRA, NICE), peer-reviewed literature, and NHS commissioning documentation — not secondary summaries. Findings are independently verified before inclusion.
Fabry Disease UK CI sources: NHS England clinical commissioning policy for agalsidase beta (no dedicated NICE technology appraisal exists), NICE HST4 Final Evaluation Determination for migalastat (2017), NICE TA915 for pegunigalsidase alfa, NHS England Highly Specialised Services specification for lysosomal storage disorders, and the UK Fabry Outcome Survey (FOS) 2023.
- MHRA approval status verified against current product licence information
- NICE HST4 and TA915 recommendations verified against published Final Evaluation/Appraisal Determinations; agalsidase beta's NHS clinical-policy basis (no dedicated NICE technology appraisal) confirmed directly on NICE.org.uk
- NHS HSS commissioning structure verified against NHS England service specification
- Clinical trial results verified against ATTRACT/FACETS and BALANCE primary trial data cited in NICE submissions
Frequently asked questions
Commission this brief
AXLRx delivers Fabry Disease competitive intelligence built for pharma and biotech commercial, access, and medical affairs teams targeting the UK NHS pathway. Custom brief in 72 hours.
Use the intake form to specify your indication, geography, and commercial question.
AXLRx analyst confirms scope, comparators, and delivery format.
Research-verified brief in 72 hours with optional analyst readout.